ProCE Banner Activity

CAR T-Cell Therapy JCAR017 in R/R DLBCL From TRANSCEND NHL 001: Correlation Between Patient Characteristics and Clinical Outcomes

Slideset Download
Conference Coverage

High patient baseline levels of tumor burden, LDH, and inflammatory biomarkers were associated with high levels of CAR T-cell expansion but increased rates of CRS and neurotoxicity.

Released: December 20, 2017

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC

ProCE Banner

Supporters

This activity is supported by educational grants from

AbbVie

AstraZeneca

Celgene

Genentech TEXT Only

Janssen Biotech Pharmacyclics Abbvie

Jazz Pharmaceuticals, Inc.

Novartis Pharmaceuticals Corporation

Pharmacyclics Inc

Seagen

Takeda Oncology